F
F2G
Discovers and develops novel drugs for the treatment of life-threatening fungal diseases
News
Open roles
F2G in the Manchester ecosystem
The F2G office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
- KNK Nominees
- MCMerifin Capital
- AVAstellas Venture
- BABankInvest
Series B and later14 investors entered at this stage
Heartcore Capital- NFNovartis Venture Fund
- ACAisling Capital
Morningside- AFAMR Action Fund
- NHNovo Holdings
- FPForbion Capital Partners
- SMSectoral Asset Management
- IGIntermediate Capital Group
- TMThe University of Manchester
Sofinnova Partners- CGCowen Group
- ASAdvent Life Sciences
- BPBrace Pharma
Ownership
Estimated cap table from Dealroom's shareholder data — share of equity by holder. Stakes as last recorded by Dealroom (2026). Percentages are indicative.
Some investors are hidden on this public profile. See the full cap table on Dealroom →
Source: Dealroom Talent Intelligence.
Patents
9 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See F2G on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

